Clinical Scorecard: Identification of Potential Tissue Diagnostic Biomarkers for Endometriosis through Bioinformatics and Machine Learning Approaches with Experimental Validation

At a Glance

Key Highlights

• Four genes (COL6A3, BGN, LAMA4, THBS2) identified as candidate tissue diagnostic markers.
• High discriminatory power with AUC > 0.80 for the identified genes.
• Immune dysregulation characterized by elevated M1 macrophages and plasma cells.
• Histopathological validation in a mice model of endometriosis.
• Significant upregulation of candidate genes confirmed via qPCR and Western blot.

Guideline-Based Recommendations

Diagnosis

• Utilize identified genes as potential biomarkers for endometriosis diagnosis.

Management

• Focus on symptom control and disease delay while considering new biomarkers for targeted therapies.

Monitoring & Follow-up

• Assess immune cell infiltration and gene expression in endometriosis tissues.

Risks

• Consider high recurrence rates and side effects associated with current treatment strategies.

Patient & Prescribing Data

Women diagnosed with endometriosis.

Current treatments focus on symptom management; novel biomarkers may guide future therapies.

Clinical Best Practices

• Incorporate bioinformatics approaches for gene identification in endometriosis.
• Validate biomarkers through experimental models and clinical data.

Related Resources & Content

• Source Article